2023 World Conference on Lung Cancer (Posters)-P2.03. Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients

P2.03. Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients - PDF(Slides)

Back to course

Pdf Summary

The study investigates a novel radiotherapy technique called EclipseRT (ERT) for treating bulky tumors. The technique combines low-dose radiation therapy (LDRT) with stereotactic body radiation therapy (SBRT). The researchers conducted experiments on mice with bulky tumors, irradiating the whole tumor with LDRT and a part of the tumor center with SBRT, along with administering αPD1. They found that ERT/αPD1 was more effective than SBRT/αPD1 or LDRT/αPD1 in controlling bulky tumors, and this effect was dependent on CD8 T cells. In a specific mouse model, ERT/αPD1 induced complete tumor regression in some cases and increased infiltration of CD8 T cells and M1 macrophages compared to other groups. Analysis of human patients with bulky tumors treated with ERT/αPD1 showed an overall response rate of 38.5%, with median progression-free survival and overall survival of 5.6 and 21.1 months, respectively. The study concludes that ERT/αPD1 showed superior efficacy in controlling bulky tumors in mice and was safe and effective in patients. It suggests that this novel radiotherapy strategy may expand the indications for radiotherapy and potentially change current practices in patients with advanced bulky tumors.

Asset Subtitle

Ren Luo

Meta Tag

Speaker Ren Luo

Topic Metastatic NSCLC: Local Therapies

Keywords

EclipseRT

ERT

radiotherapy technique

bulky tumors

low-dose radiation therapy

LDRT

stereotactic body radiation therapy

SBRT

αPD1

CD8 T cells